Big Pharma Opens Its Wallet

The dealmaking machine ran hot today. AbbVie struck the boldest note, agreeing to buy immunology biotech Apogee Therapeutics for $10.9 billion — its largest acquisition since the Allergan takeover, according to Endpoints News. The prize is Apogee's portfolio, a bid to reload AbbVie's immunology pipeline.

Merck, meanwhile, got validation for a deal it already made. Its $10.8 billion acquisition of Prometheus Biosciences delivered its first tangible payoff: the buyout's lead program succeeded in its first Phase 3 trial, beating placebo, Merck said Monday morning. Two ten-figure immunology bets — one being placed, one starting to pay off — bookended the day.

The appetite extended beyond outright M&A. Eli Lilly formed a new alliance with Swedish biotech BioArctic, the latest sign that the industry's hunger for partnerships shows no sign of cooling.

The AI Drug Hunt Goes Mainstream

Artificial intelligence threaded through the day's biggest collaborations. Insilico Medicine and SK Biopharmaceuticals unveiled a drug-discovery partnership worth up to $2.5 billion, pairing the AI specialist with the South Korean drugmaker to design new medicines — with brain drugs a central focus.

Japan's Takeda joined the chase too, teaming with Iambic, an AI-driven discovery firm — a deal BioPharma Dive framed as the newest example of a large drugmaker reaching for computational tools. Between Insilico-SK, Takeda-Iambic, and Lilly-BioArctic, the message is clear: AI is no longer a fringe experiment in pharma R&D but a standard line item in the dealmaking budget.

The FDA Softens, Again

Regulators delivered a notable reversal. The FDA cleared Regenxbio to resubmit its gene therapy for Hunter syndrome — and crucially, without requiring an additional study, according to Endpoints News and BioPharma Dive. The agency's about-face fits a broader pattern of reversing earlier drug rejections, a shift that could matter well beyond this single program.

Trial Results: One Triumph, One Stumble, One Surprise

The clinical scoreboard was mixed. In the win column, Definium Therapeutics said its LSD-based depression drug aced a Phase 3 trial, nudging psychedelic medicine a step closer to the pharmacy shelf.

Not every readout cheered. MapLight Therapeutics' autism candidate ML-004 missed in Phase 2, falling short on a key measure — though the company insists it still sees a path forward.

People and Pipelines

Leadership shuffles rounded out the day. Sanofi named Paulo Fontoura its new global head of R&D, as incumbent Houman Ashrafian exits. And a Sanofi veteran is striking out independently: Frédéric Marrache launched a new biotech, Bionyra, with $165 million to build a next generation of drugs around TL1A, a target drawing intense interest for common immune conditions.

The Takeaway

A single day captured pharma's current obsessions in miniature: immunology as the battleground (AbbVie, Merck, Bionyra's TL1A play), AI as the new must-have partner, a more permissive FDA, and the ever-present gamble of the clinic — where Definium soared and MapLight stumbled. The checkbooks are open, the algorithms are running, and the regulators are leaning yes.